OR WAIT null SECS
July 23, 2020
Fujifilm Diosynth Biotechnologies’ North Carolina site will be used to manufacture Novavax’ NVX‑CoV2373 vaccine candidate for a Phase III clinical trial.
July 22, 2020
Pending approval of the Pfizer and BioNTech mRNA-based vaccine candidate against SARS-COV-2, the companies will supply the US government with an initial 100 million doses.
July 21, 2020
Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.
The UK government has secured early access to 90 million COVID-19 vaccine doses from the BioNTech/Pfizer alliance and Valneva.
Study reports immune and T-cell response from CanSino COVID-19 vaccine candidate.
Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.
July 20, 2020
Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.
July 16, 2020
Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development.
July 09, 2020
FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives.